Nanobiotix (LTS:0QAV) Other Current Receivables: €5.54 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QAV Nanobiotix SA LTS:0QAV
28 GF Score
Price €34.70
! 3 Warning Signs
View Full Analysis

What is Nanobiotix Other Current Receivables?

Nanobiotix LTS:0QAV -5.09% 28 Other Current Receivables is €5.54 Mil as of Dec. 2025. GuruFocus rates LTS:0QAV with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Nanobiotix's Other Current Receivables for the quarter that ended in Dec. 2025 was €5.54 Mil.

Nanobiotix's quarterly Other Current Receivables increased from Dec. 2024 (€5.56 Mil) to Jun. 2025 (€7.31 Mil) but then stayed the same from Jun. 2025 (€7.31 Mil) to Dec. 2025 (€5.54 Mil).

Nanobiotix's annual Other Current Receivables declined from Dec. 2023 (€8.59 Mil) to Dec. 2024 (€5.56 Mil) and declined from Dec. 2024 (€5.56 Mil) to Dec. 2025 (€5.54 Mil).

Nanobiotix Other Current Receivables Related Terms

Nanobiotix Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Nanobiotix's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix Other Current Receivables Chart

Nanobiotix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.93 7.89 8.59 5.56 5.54

Nanobiotix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.59 8.73 5.56 7.31 5.54
LTS:0QAV
28GF Score
Nanobiotix SA LTS:0QAV
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanobiotix Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €5.54 Mil mean?
Nanobiotix (LTS:0QAV) has a Other Current Receivables of €5.54 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nanobiotix and its competitors.
Is Nanobiotix's Other Current Receivables too high?
Nanobiotix's current Other Current Receivables is €5.54 Mil. Overall, Nanobiotix has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's Other Current Receivables compare to VRTX and REGN?
Nanobiotix's Other Current Receivables of €5.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nanobiotix and its competitors. Nanobiotix's current Other Current Receivables is €5.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (LTS:0QAV) has a current Other Current Receivables of €5.54 Mil. The current Other Current Receivables is €5.54 Mil. Nanobiotix's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Nanobiotix (LTS:0QAV), the current Other Current Receivables is €5.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanobiotix Business Description

Address 60 Rue de Wattignies, Paris, FRA, 75012
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
28GF Score

Get the complete analysis for LTS:0QAV

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.70
Price